

Regulation of the 24-Hydroxylase Gene Promoter by 1,25-Dihydroxyvitamin D3 and Chemotherapeutic Drugs.

JOSEPH TAN CHENG TA

BHlthSc, Honours Sc

Thesis submitted for the degree of Doctor of Philosophy

Department of Paediatrics

The University of Adelaide

(Faculty of Health Sciences)

October 2005

Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the university library, being available for loan and photocopying.

.....

Joseph TanCheng Ta

.....

Dated

Acknowledgement

Firstly, I would like to take this opportunity to express my sincere thanks to my principal supervisor, Associate Professor Charles Hii for his continuous supervision, support, encouragement and friendship which has made my PhD study an enjoyable experience.

I would also like to thank my co-supervisor Professor Antonio Ferrante for his guidance, patience, encouragement, friendship and support.

My special thanks to Dr Prem Dwivedi, with whom I worked closely, for his valuable supervision, great discussions and long lasting friendship. Also, special thanks to Professor Brian May, Professor Howard Morris and Dr Peter O'Loughlin for their guidance and for allowing me to use their laboratories to undertake some aspects of my study. Many thanks to Barbara Nutchey, Dr Yong Lee, Dr Sophia Gao and Dr Paul Anderson for their endless help, great discussion and friendship. A special thanks to all the PhD and honours students in the Department of Immunopathology for their great friendship and jokes that we shared. Also, many thanks to Judy Ferrante, Trish Harvey, Lily Zedda, Bernadette Miller, Jess Franks, Reneé Mackenzie and other members of the Department of Immunology, WCH, for their help and in making the laboratory a wonderful place to work in.

Last but not least, I would like to express my gratitude and thanks to God for his support, wisdom and strength, my wonderful family: my parents, my brothers and sisters for their continuous support and encouragement, to my dearest wife Ya-Hui and daughter Catrina, for their endless love, support, encouragement and for making my PhD years a meaningful and worthwhile experience.

Summary

Chemotherapy in childhood cancer patients is associated with reduced bone density that can result in osteoporotic fracture in survivors. A significant proportion of paediatric patients experience a reduction in plasma 25-hydroxyvitamin D3 [25(OH)D3] and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] levels during treatment, the basis of which is unknown. A balance between the bioactivation and degradation of 1,25(OH)2D3 is responsible for maintaining homeostatic levels of 1,25(OH)2D3 at the correct set-point. Whereas the cytochrome P450 enzyme, CYP27B1 (25-hydroxyvitamin D3 1 α -hydroxylase), catalyses the hydroxylation of the precursor 25(OH)D3 to generate 1,25(OH)2D3, catabolic inactivation and cleavage of 1,25(OH)2D3 is achieved by the mitochondrial cytochrome P450 enzyme, 25-hydroxyvitamin D3 24-hydroxylase (CYP24), which is highly expressed in bone and kidney cells. Since many of the signalling pathways which regulate the expression of CYP24 are also activated by chemotherapeutic drugs, we hypothesised that the drugs could cause the degradation of plasma 25(OH)D3 and 1,25(OH)2D3 by increasing CYP24 expression, the principal means of facilitating the bio-inactivation and degradation of plasma 25(OH)D3 and 1,25(OH)2D3. Using the kidney cell-lines, COS-1 and HEK293T cells, we now report that chemotherapeutic drugs, represented by daunorubicin hydrochloride (an anthracycline antibiotics), etoposide and vincristine sulphate (vinca alkaloids and related compounds) and cisplatin (an alkylating agent), were able to enhance CYP24 promoter activity in kidney cell lines transfected with a CYP24 promoter-luciferase construct, either by themselves or in the presence of 1,25(OH)2D3. Dose-response studies with

daunorubicin hydrochloride and etoposide, two of the strongest inducers of CYP24 promoter activation under our experimental conditions, demonstrate that these drugs acted in a concentration-dependent manner. In addition to stimulating promoter activity on their own, the drugs also amplified the induction of the CYP24 promoter by 1,25(OH)₂D₃. Synergistic increases were generally observed when the cells were treated simultaneously with 1,25(OH)₂D₃ and a drug. The two kidney cell lines generally responded in a similar manner when challenged with the drugs, either in the presence or absence of 1,25(OH)₂D₃. Interestingly, the hydroxylated derivative of daunorubicin hydrochloride, doxorubicin hydrochloride which is also a commonly used chemotherapeutic drug, had no effect of promoter activity. Further studies with daunorubicin hydrochloride demonstrated that the effects of the drug per se were not mediated by oxidative stress and the vitamin D receptor was not required for daunorubicin hydrochloride per se to stimulate CYP24 promoter activity. However, daunorubicin hydrochloride caused a modest increase in the expression of the vitamin D receptor and this could contribute to its synergistic activity with 1,25(OH)₂D₃. In the presence of etoposide, there was also a tendency for the kidney cells to express higher levels of the vitamin D receptor. A key role for the extracellular signal-regulated protein kinase (ERK)1, ERK2 and ERK5 mitogen-activated protein (MAP) kinases was demonstrated for the inductive action of daunorubicin hydrochloride and etoposide, with CYP24 promoter-specific transcription factors located in the first -298bp being likely targets of the ERK activity. Studies with a dominant negative mutant of MKK4, one of the two immediate upstream activators of the c-jun N-terminal kinase isoforms, demonstrated that this MAP kinase also played a crucial role in inductive actions of the

drugs. Consistent with their use in anti-cancer therapy, all of the above drugs killed the human promyelocytic HL60 leukaemic cells at very low concentrations but had no effect on the viability of kidney or liver cells, either at concentrations used in our experiments or at higher levels. Our data provide novel biochemical evidence that some of the commonly used chemotherapeutic drugs could cause an increase in the transcriptional activation of the promoter, most likely via the MAP kinases activating the transcription factors which bind to the CYP24 promoter. Such an effect could contribute to the reduction in plasma 25(OH)D3 and 1,25(OH)2D3 in some of the patients undergoing chemotherapy.

Abbreviations

1,25(OH)2D3/ 1,25D	1,25-dihydroxyvitamin D3
24,25(OH)2D2	24,25-dihydroxyvitamin D3
25(OH)D3	25-hydroxy vitamin D3
AP1	activator protein 1
BDNF	brain-derived neurotrophic factor
CaT1	calcium transport protein
COS-1	African monkey kidney fibroblast cells
Cx43	connexin 43; a gap junction protein
CYP24	24-hydroxylase enzyme
CYP27b1	1 α -hydroxylase enzyme
DN	dominant negative
EBS	Ets-1 binding site
ECaC2	epithelial calcium channel protein
EGF	epithelial growth factor
ERK	extracellular signal-regulated kinase
ERK5	Big MAP kinase 1
EtOH	ethanol
Ets	E26
FGF-2	fibroblast growth factor-2
HEK293T	transform human embryonic kidney cells
HL60	human promyelocytic leukaemic
HPV	human papillomaviruses

IL	interleukin
JNK	c-Jun NH ₂ -terminal kinases
LY294002	PI3K inhibitor
MAPK	mitogen-activated protein kinase
MEF2	myocyte enhancer factor 2
NCX1	Na ⁺ /Ca ²⁺ exchanger pump
NF- κ B	transcription factor nuclear factor κ B
NGF	nerve growth factor
OPG	osteoprotegerin gene
PDK	phosphoinositide-dependent kinase
PI3K	phosphatidylinositol 3-kinase
PKA	protein kinase A
PKC	protein Kinase C
PMA	phorbol 12-myristate 13-acetate
PMCA	plasma membrane calcium ATPase
PTH	parathyroid hormone
RANKL	RANKL
Ras	small GTP-binding and hydrolyzing proteins
ROS	reactive oxygen species
RXR	retinoic X receptor
Sap1	Ets-domain transcription factor
SGK	serum- and glucocorticoid-inducible kinase
Sp1	specific protein 1

TGF- β	transforming growth factor-beta
Th	T helper
Tpl	tumor progression locus
TRPV	transient receptor potential vanilloid
VDR	vitamin D receptor
VDRE	vitamin D responsive element
VEGF	vascular endothelial growth factor
VP-16	etoposide
VSE	vitamin D stimulatory element

CONTENTS

DECLARATION	ii
ACKNOWLEDGEMENTS	iii
THESIS SUMMARY.....	iv
ABBREVIATIONS	vi
Chapter 1	1
Introduction	1
1.1 General Introduction.....	2
1.2 Overview of the actions of vitamin D and its metabolism	4
1.3 Biological Functions of vitamin D	7
1.3.1 Vitamin D and bone.....	7
1.3.2 Vitamin D and Calcium Absorption.....	14
1.3.3 Vitamin D and Cancer	16
1.3.4 Vitamin D and the Immune system	18
1.4 Vitamin D receptor.....	22
1.4.1 Nuclear VDR.....	22
1.4.2 Plasma membrane VDR	23
1.4.3 Regulation of VDR expression.....	24
1.4.4 Non-classical VDRs	25
1.4.4.1 Annexin II.....	25
1.4.4.2 1,25D3-MARRS	26
1.5 Non-genomic action of vitamin D.....	28
1.6 Vitamin D and intracellular signaling	29
1.6.1 Mitogen-activated protein kinases	29
1.6.1.1 ERK1/ERK2	30
1.6.1.3 JNK.....	34
1.6.2 Phosphatidylinositol 3-kinase	36
1.6.3 Protein Kinase C.....	41
1.6.4 Ras	43
1.7 Enzymes involved in vitamin D Metabolism	45

1.7.1	Hepatic 25-hydroxylase enzyme.....	45
1.7.2	Kidney 1 α -hydroxylase enzyme.....	46
1.7.2.1	Role of 1 α -hydroxylase.....	46
1.7.2.2	Regulation of the 1 α -hydroxylase	50
1.7.3	24-hydroxylase enzymes (CYP24).....	51
1.7.3.1	Regulation of the CYP24 promoter by vitamin D.....	53
1.7.3.2	Signaling pathways that regulate the CYP24 promoter in response to vitamin D.	56
1.8	Regulation of CYP24 by compounds other than vitaminD.	59
1.9	Chemotherapy and plasma vitamin D	61
1.10	Chemotherapeutic drugs.....	63
1.10.1	Categories of chemotherapeutic drugs.....	64
1.10.2	Principal targets of Chemotherapeutic drugs: the cell cycle and apoptosis.	65
1.10.3	Actions of anticancer drugs	66
1.10.3.1	Daunorubicin hydrochloride	67
1.10.3.2	Etoposide	69
1.10.3.3	Vincristine Sulfate	70
1.10.3.4	Cisplatin.....	71
1.11	Activation of cell signaling molecules by chemotherapeutic drugs.	72
1.12	Hypotheses	78
1.13	Aims	79
Chapter 2.....		80
Materials and Methods.....		80
2.1	Materials.....	81
2.1.1	General chemicals, drugs and reagents.....	81
2.1.2	Reagents for Western blots and Kinase assays	81
2.1.3	Chemotherapeutic drugs	82
2.1.4	Reagents for lysis, washing and assay buffer,	82
2.1.5	Reagents for transfection	83
2.1.6	Reagents for Luciferase Assay	83
2.1.7	Antibodies.....	83
2.1.8	Serum, Culture media and buffers	83
2.1.9	Flasks and plates for culture	84
2.1.20	Cell lines	84
2.1.21	Plasmids/Vectors	84
2.1.22	Buffers and Solutions	88
2.1.23	Reagents for RNA extraction and real time PCR	89

2.2	Methods.....	90
2.2.1	Cell Culture	90
2.2.1.1	Culture of HEK293T and COS-1 cells.....	90
2.2.1.2	Cell Culture for kinase assay and for western blotting.	90
2.2.1.3	Culture of HL 60 cells.....	91
2.2.2	Cell Viability Assay using trypan blue.....	91
2.2.3	Plasmid DNA Preparation and Transfection.....	92
2.2.3.1	Midi-preparation using midi-plasmid DNA preparation kit (Qiagen)	92
2.2.3.2	Large scale preparation by cesium-chloride (CsCl) density gradient procedure.....	92
2.2.3.4	Dual Luciferase assay	94
2.2.4	Preparation of cell lysates	94
2.2.5	Lowry's Protein determination	95
2.2.6	Kinase Assay and Western Blotting	95
2.2.6.1	Purification of GST-jun (1-79)	95
2.2.6.2	JNK kinase assay	96
2.2.6.3	ERK1/ERK2/ERK5 kinase assays.....	97
2.2.6.4	Western Blotting.....	97
2.2.6.5	Western Blot recycling	99
2.2.7	Quantification of mRNA expression using real-time PCR.....	99
2.2.7.1	RNA Extraction	99
2.2.7.2	Generation of cDNA.....	99
2.2.7.3	Real-time PCR.....	100
2.2.8	Statistics.....	100

Chapter 3..... 101

Effects of chemotherapeutic drugs on the induction of the CYP24 promoter in kidney cells..... 101

3.1	Introduction	102
3.2	Methods for investigating CYP24 promoter induction.....	103
3.3	Results	104
3.3.1	Effects of chemotherapeutic drugs on the activity of the -1.4kb CYP24 promoter in COS-1 and HEK293T kidney cells.....	104
3.3.2	Effects of chemotherapeutic drugs on the activity of the -298 bp CYP24 promoter in COS-1 kidney cells.....	108
3.3.3	Daunorubicin hydrochloride stimulated the -1.4kb CYP24 promoter activity in a dose-dependent manner in COS-1 kidney cells.....	112

3.3.4	Dose-dependent effect of daunorubicin hydrochloride on the -298bp CYP24 promoter in COS-1 cells and HEK293T cells.	114
3.3.5	Etoposide stimulated the -1.4kb CYP24 promoter activity in a dose-dependent manner in COS-1 kidney cells.	117
3.3.6	Doxorubicin hydrochloride did not stimulate the activity of the -298bp CYP24 promoter or enhance CYP24 induction by 1,25(OH)2D3 in COS-1 cells.	119
3.4	Summary	121
Chapter 4 Mechanism I.....		124
Mechanism of action of daunorubicin hydrochloride and etoposide on CYP24 promoter activity: Role of reactive oxygen species (ROS), VDR, VDRE and Sp1.....		124
4.1	ROS are not required for CYP24 promoter induction by daunorubicin hydrochloride and etoposide in COS-1 cells.	125
4.2	Over expression of VDR did not enhance CYP24 promoter induction by daunorubicin hydrochloride in COS-1 and HEK293T cells.	127
4.3	VDRE and GC box are not involved in CYP24 promoter induction by daunorubicin hydrochloride in COS-1 cells.	131
4.4	Daunorubicin hydrochloride did not alter the activity of the VDR in COS-1 cells.....	133
4.5	Daunorubicin hydrochloride and etoposide increased the expression of VDR in COS-1 and HEK293T cells.	135
4.6	Summary	138
Chapter 5 Mechanism II		139
Role of MAP Kinases in 1,25(OH)2D3 mediated transactivation regulation of the CYP24 promoter in COS-1 cells.....		139
5.1	Introduction	140
5.1.1	Vectors used:	142
5.2	Results:	143
5.2.1	1,25(OH)2D3 stimulated phosphorylation of ERK1/ERK2 in COS-1 cells.	143
5.2.2	1,25(OH)2D3 stimulated the activity of ERK5 activity in COS-1 cells	145
5.2.3	Dominant negative ERK1 and MEK5 inhibited 1,25(OH)2D3 mediated induction of the CYP24 promoter.....	148

5.2.4	Dominant negative Ras inhibited the stimulation of ERK1/ERK2 activity by 1,25(OH)2D3 in COS-1 cells.....	151
5.2.5	Dominant negative Ras inhibited the stimulation of ERK5 activity by 1,25(OH)2D3 in COS-1 cells.	152
5.2.6	Dominant negative Ras inhibited CYP24 promoter induction by 1,25(OH)2D3	155
5.2.7	ERK2 interacted with RXR α independently of 1,25(OH)2D3.....	155
5.2.8	Phosphorylation of RXR α was dependent on the interaction between activated ERK1/ERK2 and RXR α	158
5.2.9	RXR phosphorylation played an important role in CYP24 induction by 1,25(OH)2D3. ...	160
5.2.10	Interaction between ERK5 and Ets-1 was 1,25(OH)2D3-dependent.....	162
5.2.11	1,25(OH)2D3 stimulated the phosphorylation of Ets-1 protein.....	164
5.2.12	Phosphorylation of Ets-1 requires the activation of HA-ERK5 by MEK5 and Ras.	166
5.2.13	CYP24 promoter induction by 1,25(OH)2D3 required the Ets binding site (EBS) and the ERK5 module	169
5.3	Summary	171

Chapter 6 Mechanism III..... 173

Role of MAP kinases, PI3K and PKC in mediating CYP24 promoter induction by daunorubicin hydrochloride and etoposide. 173

6.1	Introduction	174
6.2	Results	174
6.2.1	Dominant negative ERK1 and MEK5 prevent the induction of CYP24 promoter activity by daunorubicin hydrochloride in COS-1 cells.	174
6.2.2	Daunorubicin hydrochloride stimulated the activities of ERK1/ERK2 and ERK5 in COS-1 cells.	175
6.2.3	Dominant negative MKK4 inhibited daunorubicin hydrochloride induction of CYP24 promoter activity in COS-1 cells.	177
6.2.4	Daunorubicin hydrochloride stimulated JNK activity in COS-1 cells.....	180
6.2.5	Dominant negative PKC ζ inhibited daunorubicin hydrochloride induction of CYP24 promoter activity in COS-1 cells.	183
6.2.6	Inhibitor of PI3K (LY294002) suppressed daunorubicin hydrochloride induction of CYP24 promoter activity in COS-1 cells.	186
6.2.7	Inhibition of daunorubicin hydrochloride-mediated transcriptional activation of the CYP24 promoter activity by dominant negative ERK1 and MEK5 in HEK293T cells.....	188

6.2.8	Daunorubicin hydrochloride stimulated ERK1/ERK2 and ERK5 activities in HEK293T cells.	191
6.2.9	Effect of dominant negative MKK4 on daunorubicin hydrochloride-and 1,25(OH)2D3-mediated induction of CYP24 promoter activity in HEK293T cells.	194
6.2.10	Daunorubicin hydrochloride stimulated JNK activity in HEK293T cells.	196
6.2.11	PKC ζ was not required for the induction of the CYP24 promoter by daunorubicin hydrochloride and 1,25(OH)2D3 in HEK293T cells.	196
6.2.12	Role of MAP Kinases and PKC ζ in the induction of CYP24 promoter by etoposide in COS-1 cells.	198
6.2.13	Dominant negative ERK1 and not MEK5 inhibited etoposide mediated induction of the CYP24 promoter activity in COS-1 cells.	200
6.2.14	Etoposide stimulated ERK1/ERK2 activity in COS-1 cells.	202
6.2.15	Dominant negative MKK4 but not PKC ζ inhibited etoposide-mediated induction of the CYP24 promoter activity in COS-1 cells.	202
6.2.16	Etoposide stimulated JNK activity in COS-1 cells.	205
6.3	Summary	208
Chapter 7		209
Effects of chemotherapeutic drugs on endogenous CYP24 mRNA expression in kidney cells		209
7.1	Introduction	210
7.2	Methods	210
7.3	Results	211
7.3.1	Daunorubicin hydrochloride and etoposide inhibited the expression of endogenous CYP24 by 1,25(OH)2D3.	211
7.3.2	Pre-treatment of 1,25(OH)2D3 prevented etoposide from suppressing the induction of CYP24 mRNA expression by 1,25(OH)2D3.	211
7.3.3	Etoposide stimulated the degradation of CYP24 mRNA.	214
7.4	Summary	216
Chapter 8		217
Discussion		217
8.1	Discussion	218
8.1.1	Anti-cancer drugs and CYP24 promoter activity	218
8.1.2	Cytotoxic effects of the drugs in HL60 cells but not in kidney cells	220
8.1.3	Lack of a role for the VDR and VDREs in the actions of the drugs	221

8.1.4	Daunorubicin and etoposide increased the expression of the VDR	222
8.1.5	Reactive oxygen species and the promoter inducing effect of daunorubicin and etoposide	223
8.1.6	Non-genomic actions of 1,25(OH)2D3 involving intracellular signalling molecules	224
8.1.7	Anti-cancer drugs and intracellular signalling molecules in CYP24 promoter activation..	227
8.1.8	Suppression of CYP24 mRNA induction by daunorubicin and etoposide	230
8.1.9	Clinical implications of this work and future directions.....	231
8.2	Summary	234

References..... 237